Short Description

ER & PR receptor assays are routinely performed on Breast carcinoma to assess responsiveness to endocrine therapy and prognosis. Her-2 expression predicts responsiveness to Herceptin therapy. Ki-67 in addition is a useful prognositc marker. Together ER, PR, Her-2 and Ki 67 help to predict prognosis and serve as surrogate IHC markers for molecular subtypes of Breast Cancer. Reporting through digital images using Visiopharm AI algorithms enhances the sensitivity of the assay.

PreTest Information

Provide a copy of the Histopathology report. Indicate site of biopsy and provide Clinical history.

Detail Description

IMMUNOHISTOCHEMISTRY DIGITAL BREAST CANCER PANEL 4 Test

Breast cancer is one of the most common types of cancer that affect women worldwide. Early detection of breast cancer can significantly improve the chances of successful treatment and recovery. DNA Labs India offers the Immunohistochemistry Digital Breast Cancer Panel 4 Test, which is a reliable and accurate way to diagnose breast cancer.

What is the Immunohistochemistry Digital Breast Cancer Panel 4 Test?

The Immunohistochemistry Digital Breast Cancer Panel 4 Test is a diagnostic test that uses immunohistochemistry technology to identify the presence of specific proteins in breast tissue. This test can help determine if a breast tumor is benign or malignant, and if it is malignant, the test can provide information about the type of breast cancer and the best course of treatment.

Test Cost

The cost of the Immunohistochemistry Digital Breast Cancer Panel 4 Test is INR 10,000.

Symptoms of Breast Cancer

Breast cancer can present with several symptoms, including:

• A lump or thickening in the breast or underarm
• A change in the size, shape, or appearance of the breast
• Nipple discharge or inverted nipple
• Redness or scaling of the breast skin or nipple
• Breast pain or tenderness

It is important to note that not all breast lumps are cancerous, and not all breast cancers present with symptoms. Therefore, regular breast cancer screenings are essential for early detection and treatment.

Diagnosis of Breast Cancer

The diagnosis of breast cancer typically involves a combination of imaging tests and biopsy. Imaging tests, such as mammography, ultrasound, or MRI, can help identify suspicious areas in the breast tissue. A biopsy involves removing a small sample of breast tissue for laboratory analysis to determine if cancer is present.

The Immunohistochemistry Digital Breast Cancer Panel 4 Test is often used in conjunction with a biopsy to provide additional information about the type and severity of breast cancer.

Conclusion

The Immunohistochemistry Digital Breast Cancer Panel 4 Test is an important tool in the diagnosis of breast cancer. Early detection of breast cancer can significantly improve the chances of successful treatment and recovery. If you are experiencing any symptoms of breast cancer or have concerns about your breast health, it is important to speak with your healthcare provider and schedule regular breast cancer screenings.

Contact DNA Labs India to schedule your Immunohistochemistry Digital Breast Cancer Panel 4 Test today.

ER & PR receptor assays are routinely performed on Breast carcinoma to assess responsiveness to endocrine therapy and prognosis. Her-2 expression predicts responsiveness to Herceptin therapy. Ki-67 in addition is a useful prognositc marker. Together ER, PR, Her-2 and Ki 67 help to predict prognosis and serve as surrogate IHC markers for molecular subtypes of Breast Cancer. Reporting through digital images using Visiopharm AI algorithms enhances the sensitivity of the assay.